Iovance Biotherapeutics (IOVA) Given a $22.00 Price Target at HC Wainwright
Iovance Biotherapeutics (NASDAQ:IOVA) has been given a $22.00 price target by equities research analysts at HC Wainwright in a research report issued to clients and investors on Thursday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 30.95% from the company’s current price.
A number of other brokerages have also recently commented on IOVA. ValuEngine raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. BidaskClub raised Iovance Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. Oppenheimer upped their price target on Iovance Biotherapeutics from $13.00 to $19.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Wells Fargo & Co reaffirmed a “buy” rating and issued a $23.00 price target on shares of Iovance Biotherapeutics in a research note on Monday, January 29th. Finally, B. Riley reaffirmed a “buy” rating and issued a $18.00 price target on shares of Iovance Biotherapeutics in a research note on Thursday, January 25th. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Iovance Biotherapeutics has an average rating of “Buy” and an average target price of $18.75.
Shares of Iovance Biotherapeutics (NASDAQ IOVA) opened at $16.80 on Thursday. The company has a market capitalization of $1,398.22, a PE ratio of -12.92 and a beta of 5.89. Iovance Biotherapeutics has a 52 week low of $4.45 and a 52 week high of $18.15.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/10/iovance-biotherapeutics-iova-given-a-22-00-price-target-at-hc-wainwright.html.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.